Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia.

Abstract

Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia. ZTD was found to be safe, as effective as HLP, and to produce significantly fewer extrapyramidal side-effects (EPS).

• Authors: T Silverstone, S Levine, H L Freeman, A Dubini
• Journal: The British journal of psychiatry : the journal of mental science (Br J Psychiatry) Vol. 145 Pg. 294-9 (Sep 1984) ISSN: 0007-1250 [Print] England
• PMID: 6148118 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Antipsychotic Agents
• Imidazoles
• zetidoline
• Haloperidol

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Antipsychotic Agents (therapeutic use)
• Basal Ganglia Diseases (chemically induced)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Haloperidol (adverse effects, therapeutic use)
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Male
• Middle Aged
• Schizophrenia (drug therapy)